ABSI
Absci Corporation
Biotechnology
Market Cap$894M
5Y Perf.-79.3%
Compare Stocks
5 / 10Try these comparisons:
Stock Comparison
ABSI vs SDGR vs RXRX vs TWST vs ILMN
Revenue, margins, valuation, and 5-year total return — side by side.
SDGR
Schrödinger, Inc.
Medical - Healthcare Information Services
Market Cap$992M
5Y Perf.-80.6%
RXRX
Recursion Pharmaceuticals, Inc.
Biotechnology
Market Cap$1.46B
5Y Perf.-89.1%
TWST
Twist Bioscience Corporation
Medical - Diagnostics & Research
Market Cap$3.65B
5Y Perf.-53.8%
ILMN
Illumina, Inc.
Medical - Diagnostics & Research
Market Cap$21.07B
5Y Perf.-70.6%
ABSI vs SDGR vs RXRX vs TWST vs ILMN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ABSI | SDGR | RXRX | TWST | ILMN |
|---|---|---|---|---|---|
| Industry | Biotechnology | Medical - Healthcare Information Services | Biotechnology | Medical - Diagnostics & Research | Medical - Diagnostics & Research |
| Market Cap | $894M | $992M | $1.46B | $3.65B | $21.07B |
| Revenue (TTM) | $2M | $255M | $66M | $409M | $4.39B |
| Net Income (TTM) | $-118M | $-103M | $-560M | $-81M | $853M |
| Gross Margin | -13.4% | 55.3% | -34.4% | 52.1% | 67.1% |
| Operating Margin | -60.3% | -64.7% | -8.8% | -33.9% | 20.9% |
| Forward P/E | — | — | — | — | 27.2x |
| Total Debt | $5M | $109M | $78M | $137M | $2.55B |
| Cash & Equiv. | $20M | $231M | $743M | $183M | $1.42B |
ABSI vs SDGR vs RXRX vs TWST vs ILMN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
ABSI
SDGR
RXRX
TWST
ILMN
| Stock | Jul 21 | May 26 | Return |
|---|---|---|---|
| Absci Corporation (ABSI) | 100 | 20.7 | -79.3% |
| Schrödinger, Inc. (SDGR) | 100 | 19.4 | -80.6% |
| Recursion Pharmaceu… (RXRX) | 100 | 10.9 | -89.1% |
| Twist Bioscience Co… (TWST) | 100 | 46.2 | -53.8% |
| Illumina, Inc. (ILMN) | 100 | 29.4 | -70.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: ABSI vs SDGR vs RXRX vs TWST vs ILMN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ILMN leads in 4 of 7 categories (5-stock set), making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Absci Corporation is the stronger pick specifically for recent price momentum and sentiment. RXRX also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
ABSI
Absci Corporation
The Defensive Pick
ABSI is the #2 pick in this set and the best alternative if sleep-well-at-night and defensive is your priority.
- Lower volatility, beta 2.82, Low D/E 2.8%, current ratio 6.57x
- Beta 2.82, current ratio 6.57x
- +116.2% vs SDGR's -44.0%
Best for: sleep-well-at-night and defensive
SDGR
Schrödinger, Inc.
The Growth Angle
SDGR lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
RXRX
Recursion Pharmaceuticals, Inc.
The Growth Play
RXRX ranks third and is worth considering specifically for growth exposure.
- Rev growth 26.9%, EPS growth 14.8%, 3Y rev CAGR 23.5%
- 26.9% revenue growth vs ABSI's -38.2%
Best for: growth exposure
TWST
Twist Bioscience Corporation
The Long-Run Compounder
TWST is the clearest fit if your priority is long-term compounding.
- 318.1% 10Y total return vs ILMN's 0.7%
Best for: long-term compounding
ILMN
Illumina, Inc.
The Income Pick
ILMN carries the broadest edge in this set and is the clearest fit for income & stability.
- beta 1.23
- Better valuation composite
- 19.4% margin vs ABSI's -73.1%
- Beta 1.23 vs RXRX's 3.18
Best for: income & stability
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | RXRX | 26.9% revenue growth vs ABSI's -38.2% |
| Value | ILMN | Better valuation composite |
| Quality / Margins | ILMN | 19.4% margin vs ABSI's -73.1% |
| Stability / Safety | ILMN | Beta 1.23 vs RXRX's 3.18 |
| Dividends | Tie | None of these 5 stocks pay a meaningful dividend |
| Momentum (1Y) | ABSI | +116.2% vs SDGR's -44.0% |
| Efficiency (ROA) | ILMN | 13.4% ROA vs ABSI's -54.7%, ROIC 16.8% vs -58.0% |
ABSI vs SDGR vs RXRX vs TWST vs ILMN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
FY 2025
FY 2025
FY 2025
ABSI vs SDGR vs RXRX vs TWST vs ILMN — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLILMNLAGGINGRXRX
Who Leads Where
ILMN leads in 2 of 6 categories
TWST leads 1 • ABSI leads 0 • SDGR leads 0 • RXRX leads 0 • 2 tied
Explore the data ↓RXRXRecursion Pharmaceuti…
0leads
SDGRSchrödinger, Inc.
0leads
ABSIAbsci Corporation
0leads
TWSTTwist Bioscience Corp…
1leads
ILMNIllumina, Inc.
2leads
6 Total Categories
CATEGORYLEADERvs TWSTvs ABSIMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ILMN4/6
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ILMN6/9
Total Returns1Y, 3Y, 5Y total returns with dividends
TWST5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ILMN leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ILMN is the larger business by revenue, generating $4.4B annually — 2708.8x ABSI's $2M. ILMN is the more profitable business, keeping 19.4% of every revenue dollar as net income compared to ABSI's -73.1%. On growth, TWST holds the edge at +19.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ABSIAbsci Corporation | SDGRSchrödinger, Inc. | RXRXRecursion Pharmac… | TWSTTwist Bioscience … | ILMNIllumina, Inc. |
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $2M | $255M | $66M | $409M | $4.4B |
| EBITDAEarnings before interest/tax | -$116M | -$159M | -$521M | -$115M | $1.1B |
| Net IncomeAfter-tax profit | -$118M | -$103M | -$560M | -$81M | $853M |
| Free Cash FlowCash after capex | -$99M | -$148M | -$326M | -$95M | $989M |
| Gross MarginGross profit ÷ Revenue | -13.4% | +55.3% | -34.4% | +52.1% | +67.1% |
| Operating MarginEBIT ÷ Revenue | -60.3% | -64.7% | -8.8% | -33.9% | +20.9% |
| Net MarginNet income ÷ Revenue | -73.1% | -40.6% | -8.4% | -19.8% | +19.4% |
| FCF MarginFCF ÷ Revenue | -60.8% | -58.2% | -4.9% | -23.2% | +22.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | -100.0% | -1.6% | -56.1% | +19.3% | +4.8% |
| EPS Growth (YoY)Latest quarter vs prior year | +9.5% | +1.2% | +56.0% | -7.6% | +6.1% |
ILMN leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
Evenly matched — SDGR and RXRX and TWST and ILMN each lead in 1 of 4 comparable metrics.
Valuation Metrics
| Metric | ABSIAbsci Corporation | SDGRSchrödinger, Inc. | RXRXRecursion Pharmac… | TWSTTwist Bioscience … | ILMNIllumina, Inc. |
|---|---|---|---|---|---|
| Market CapShares × price | $894M | $992M | $1.5B | $3.6B | $21.1B |
| Enterprise ValueMkt cap + debt − cash | $879M | $871M | $797M | $3.6B | $22.2B |
| Trailing P/EPrice ÷ TTM EPS | -6.85x | -9.42x | -2.27x | -45.03x | 25.45x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | — | 27.22x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | 6.01x |
| EV / EBITDAEnterprise value multiple | — | — | — | — | 19.58x |
| Price / SalesMarket cap ÷ Revenue | 319.22x | 3.88x | 19.58x | 9.68x | 4.86x |
| Price / BookPrice ÷ Book value/share | 4.15x | 2.68x | 1.29x | 7.40x | 7.95x |
| Price / FCFMarket cap ÷ FCF | — | 79.66x | — | — | 22.63x |
Evenly matched — SDGR and RXRX and TWST and ILMN each lead in 1 of 4 comparable metrics.
Profitability & Efficiency
ILMN leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
ILMN delivers a 32.8% return on equity — every $100 of shareholder capital generates $33 in annual profit, vs $-64 for ABSI. ABSI carries lower financial leverage with a 0.03x debt-to-equity ratio, signaling a more conservative balance sheet compared to ILMN's 0.94x. On the Piotroski fundamental quality scale (0–9), ILMN scores 8/9 vs TWST's 4/9, reflecting strong financial health.
| Metric | ABSIAbsci Corporation | SDGRSchrödinger, Inc. | RXRXRecursion Pharmac… | TWSTTwist Bioscience … | ILMNIllumina, Inc. |
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -63.6% | -30.8% | -54.3% | -17.5% | +32.8% |
| ROA (TTM)Return on assets | -54.7% | -15.3% | -40.6% | -12.5% | +13.4% |
| ROICReturn on invested capital | -58.0% | -39.4% | -95.8% | -26.9% | +16.8% |
| ROCEReturn on capital employed | -65.9% | -28.6% | -50.1% | -24.9% | +17.6% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 4 | 4 | 4 | 8 |
| Debt / EquityFinancial leverage | 0.03x | 0.30x | 0.07x | 0.29x | 0.94x |
| Net DebtTotal debt minus cash | -$15M | -$121M | -$665M | -$46M | $1.1B |
| Cash & Equiv.Liquid assets | $20M | $231M | $743M | $183M | $1.4B |
| Total DebtShort + long-term debt | $5M | $109M | $78M | $137M | $2.6B |
| Interest CoverageEBIT ÷ Interest expense | -865.97x | — | -336.46x | — | 12.09x |
ILMN leads this category, winning 6 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
TWST leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in TWST five years ago would be worth $5,015 today (with dividends reinvested), compared to $1,179 for RXRX. Over the past 12 months, ABSI leads with a +116.2% total return vs SDGR's -44.0%. The 3-year compound annual growth rate (CAGR) favors TWST at 63.5% vs SDGR's -21.8% — a key indicator of consistent wealth creation.
| Metric | ABSIAbsci Corporation | SDGRSchrödinger, Inc. | RXRXRecursion Pharmac… | TWSTTwist Bioscience … | ILMNIllumina, Inc. |
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +59.3% | -26.1% | -22.1% | +80.7% | +3.2% |
| 1-Year ReturnPast 12 months | +116.2% | -44.0% | -22.0% | +78.6% | +81.7% |
| 3-Year ReturnCumulative with dividends | +304.9% | -52.1% | -41.6% | +336.9% | -27.1% |
| 5-Year ReturnCumulative with dividends | -73.4% | -80.6% | -88.2% | -49.9% | -62.8% |
| 10-Year ReturnCumulative with dividends | -73.4% | -53.6% | -81.8% | +318.1% | +0.7% |
| CAGR (3Y)Annualised 3-year return | +59.4% | -21.8% | -16.4% | +63.5% | -10.0% |
TWST leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — ABSI and ILMN each lead in 1 of 2 comparable metrics.
Risk & Volatility
ILMN is the less volatile stock with a 1.23 beta — it tends to amplify market swings less than RXRX's 3.18 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ABSI currently trades 92.2% from its 52-week high vs RXRX's 45.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ABSIAbsci Corporation | SDGRSchrödinger, Inc. | RXRXRecursion Pharmac… | TWSTTwist Bioscience … | ILMNIllumina, Inc. |
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.77x | 1.65x | 2.99x | 2.41x | 1.20x |
| 52-Week HighHighest price in past year | $6.24 | $27.63 | $7.18 | $66.00 | $155.53 |
| 52-Week LowLowest price in past year | $2.24 | $10.95 | $2.80 | $23.30 | $73.86 |
| % of 52W HighCurrent price vs 52-week peak | +92.2% | +48.1% | +45.5% | +88.7% | +89.2% |
| RSI (14)Momentum oscillator 0–100 | 83.6 | 59.8 | 49.5 | 57.0 | 65.2 |
| Avg Volume (50D)Average daily shares traded | 4.4M | 1.3M | 12.5M | 1.2M | 1.5M |
Evenly matched — ABSI and ILMN each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: ABSI as "Buy", SDGR as "Buy", RXRX as "Hold", TWST as "Buy", ILMN as "Buy". Consensus price targets imply 236.4% upside for RXRX (target: $11) vs 3.3% for TWST (target: $61).
| Metric | ABSIAbsci Corporation | SDGRSchrödinger, Inc. | RXRXRecursion Pharmac… | TWSTTwist Bioscience … | ILMNIllumina, Inc. |
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Hold | Buy | Buy |
| Price TargetConsensus 12-month target | $6.16 | $18.00 | $11.00 | $60.50 | $147.38 |
| # AnalystsCovering analysts | 12 | 12 | 10 | 13 | 50 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | +0.0% | +3.5% |
Insufficient data to determine a leader in this category.
Key Takeaway
ILMN leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). TWST leads in 1 (Total Returns). 2 tied.
Best OverallIllumina, Inc. (ILMN)Leads 2 of 6 categories
Loading custom metrics...
ABSI vs SDGR vs RXRX vs TWST vs ILMN: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is ABSI or SDGR or RXRX or TWST or ILMN a better buy right now?
For growth investors, Recursion Pharmaceuticals, Inc.
(RXRX) is the stronger pick with 26. 9% revenue growth year-over-year, versus -38. 2% for Absci Corporation (ABSI). Illumina, Inc. (ILMN) offers the better valuation at 25. 5x trailing P/E (27. 2x forward), making it the more compelling value choice. Analysts rate Absci Corporation (ABSI) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ABSI or SDGR or RXRX or TWST or ILMN?
Over the past 5 years, Twist Bioscience Corporation (TWST) delivered a total return of -49.
9%, compared to -88. 2% for Recursion Pharmaceuticals, Inc. (RXRX). Over 10 years, the gap is even starker: TWST returned +306. 1% versus RXRX's -81. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ABSI or SDGR or RXRX or TWST or ILMN?
By beta (market sensitivity over 5 years), Illumina, Inc.
(ILMN) is the lower-risk stock at 1. 20β versus Recursion Pharmaceuticals, Inc. 's 2. 99β — meaning RXRX is approximately 149% more volatile than ILMN relative to the S&P 500. On balance sheet safety, Absci Corporation (ABSI) carries a lower debt/equity ratio of 3% versus 94% for Illumina, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — ABSI or SDGR or RXRX or TWST or ILMN?
By revenue growth (latest reported year), Recursion Pharmaceuticals, Inc.
(RXRX) is pulling ahead at 26. 9% versus -38. 2% for Absci Corporation (ABSI). On earnings-per-share growth, the picture is similar: Illumina, Inc. grew EPS 170. 9% year-over-year, compared to 10. 6% for Absci Corporation. Over a 3-year CAGR, RXRX leads at 23. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — ABSI or SDGR or RXRX or TWST or ILMN?
Illumina, Inc.
(ILMN) is the more profitable company, earning 19. 6% net margin versus -41. 1% for Absci Corporation — meaning it keeps 19. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ILMN leads at 19. 9% versus -44. 5% for ABSI. At the gross margin level — before operating expenses — ILMN leads at 66. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is ABSI or SDGR or RXRX or TWST or ILMN more undervalued right now?
Analyst consensus price targets imply the most upside for RXRX: 236.
4% to $11. 00.
07Which pays a better dividend — ABSI or SDGR or RXRX or TWST or ILMN?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is ABSI or SDGR or RXRX or TWST or ILMN better for a retirement portfolio?
For long-horizon retirement investors, Illumina, Inc.
(ILMN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 20)). Recursion Pharmaceuticals, Inc. (RXRX) carries a higher beta of 2. 99 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ILMN: +3. 0%, RXRX: -81. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between ABSI and SDGR and RXRX and TWST and ILMN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: ABSI is a small-cap quality compounder stock; SDGR is a small-cap high-growth stock; RXRX is a small-cap high-growth stock; TWST is a small-cap high-growth stock; ILMN is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(ABSI: -100.0% · SDGR: -1.6%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.